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In patients with left heart failure, micro-RNAs (miRNAs) have been shown to be of diagnostic
and prognostic value. The present study aims to identify those miRNAs in patients with uni-
ventricular heart (UVH) disease that may be associated with overt heart failure.
Methods
A large panel of human miRNA arrays were used to determine miRNA expression profiles in
the blood of 48 UVH patients and 32 healthy controls. For further selection, the most abun-
dantly expressed miRNA arrays were related to clinical measures of heart failure and
selected miRNAs validated by polymerase chain reaction were used for the prediction of
overt heart failure and all-cause mortality.
Results
According to microarray analysis, 50 miRNAs were found to be significantly abundant in
UVH patients of which miR-150-5p was best related to heart failure parameters. According
to ROC analysis, NT-proBNP levels (AUC 0.940, 95% CI 0.873–1.000; p = 0.001), miR-
150-5p (AUC 0.905, 95% CI 0.779–1.000; p = 0.001) and a higher NYHA class� III (AUC
0.893, 95% CI 0.713–1.000; p = 0.002) were the 3 most significant predictors of overt heart
failure. Using a combined biomarker model, AUC increased to 0.980 indicating an additive
value of miR-150-5p. Moreover, in the multivariate analysis, a higher NYHA class� III (p =
0.005) and miR-150-5p (p = 0.006) turned out to be independent predictors of overt heart
failure.
Conclusion
In patients with UVH, miR-150-5p is an independent predictor of overt heart failure and thus
may be used in the risk assessment of these patients.
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Introduction
Univentricular heart (UVH) disease is a complex and rare congenital cardiac disorder with a
functionally single ventricular chamber of right or left ventricular morphology. It accounts for
~7.7% of all congenital heart defects and encompasses a great variety of heart lesions [1]. After
several palliative surgical stages resulting in a complete Fontan procedure in early infancy, sur-
vival and outcome are mainly dependent on the morphology and function of the major ven-
tricular chamber as well as pulmonary hemodynamics [2, 3]. During long-term follow-up,
patients with UVH are prone to develop heart failure, arrhythmias, thromboembolic events
and congestive hepatopathy including liver fibrosis, cirrhosis or hepatocellular carcinoma [4–
10]. Moreover, all these late complications are strongly associated with worsening of outcome
and thus have prognostic impact in this patient population [4, 5].
Studies have demonstrated that microRNAs (miRNAs) play a critical role in the pathogenic
mechanisms of heart failure such as remodeling, hypertrophy or apoptosis [11, 12]. Moreover,
the etiology but also the different stages of heart failure are associated with differentially
expressed miRNA patterns [13–16]. Since extracellular circulating miRNAs are remarkably
stable [17], they can be used as diagnostic and prognostic markers for heart failure [16, 18] or
to guide response to therapy [19, 20].
In patients with congenital heart disease, miRNAs have been shown to be differentially
expressed according to the underlying heart defect [21]. Furthermore, they may also indicate
disease progression or the presence of symptomatic heart failure as has been shown previously
in patients after surgical repair of tetralogy of Fallot [22]. To date, there is only one study avail-
able investigating miRNAs in children with UVH and different stages of palliation in infancy
[23]. However, no data are available on the specific miRNAs that are involved in the onset or
progression of heart failure in adolescent and adult UVH patients. Therefore, the aim of our
study was to analyze miRNAs in the blood of adolescent and adult UVH patients in order to
identify those miRNAs that are associated with clinical measures of heart failure and to assess
their predictive value for the occurrence of overt heart failure as well as for all-cause mortality
in this cohort of patients.
Materials and methods
Patients
A total of 48 consecutive UVH patients seen in our outpatient clinic between 02/05/2015 and
18/06/2018 were enrolled in the present study and comprised 32/48 (66.7%) patients with a
morphological left and 16/32 (50%) patients with a morphological right ventricle. In the left
ventricle UVH group, 12 patients presented with tricuspid atresia, 12 patients with double
inlet left ventricle and 8 patients with pulmonary atresia with or without ventricular septal
defect. In the right ventricle UVH group, 8 patients had hypoplastic left heart syndrome or
mitral atresia and 8 patients double outlet right ventricle with pulmonary stenosis. Mean age
was 22.8 ± 10.1 years (range 11–46 years). 17 patients were female and 31 patients male.
Patients’ characteristics are illustrated in Table 1.
At enrollment, a structured protocol including a 12-lead surface electrocardiogram, a physi-
cal examination, measurement of blood pressure and transcutaneous oxygen saturation at rest,
two-dimensional echocardiography as well as a venous blood draw for routine laboratory
parameters and blood sampling were performed. The study protocol has been described in
detail previously [24]. Follow-up visits were performed annually according to the above men-
tioned protocol and with special emphasis on the occurrence or presence of overt heart failure
(i.e. clinical signs of acute heart failure such as pleural effusions, ascites or peripheral edema
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associated with significant weight gain) as well as on survival status. Follow-up was extended
to 30/06/2019 and comprised a mean time of 35.0 ± 13.8 months.
Thirty-two healthy volunteers served as controls and were matched to UVH patients
according to age and gender (S1 Dataset). Control group participants were recruited mainly
within our institution and consisted of medical students, medical staff or adolescents admitted
for unspecific chest pain. All volunteers underwent physical examination and two-dimensional
echocardiography to verify the absence of any heart abnormality as well as venous blood sam-
pling after echocardiography. The study complies with the Declaration of Helsinki, was
approved by the Saarland medical association ethical board and all subjects or their guardians
gave written and informed consent before enrollment.
Sample preparation and RNA isolation
In all patients and controls, blood samples for miRNA detection were collected in PAXgene™
blood tubes (Becton–Dickinson, Heidelberg, Germany) shortly after echocardiographic evalu-
ation. All PAXgene™ blood tubes were stored at room temperature for at least 24 hours to
ensure complete lysis of the blood cells, then stored at -20˚C for several days and finally trans-
ferred to -80˚C for long-term storage until RNA isolation. Total RNA including miRNAs was
isolated from blood samples using PAXgene™ Blood miRNA Kit on the QIAcube™ robot (Qia-
gen, Hilden, Germany) following the manufacturer’s recommendations and included DNase I
treatment (Qiagen). To confirm the absence of genomic DNA contamination, a conventional








Age at follow-up (years) 22.8 ± 10.1 23.6 ± 10.8 21.0 ± 8.6 ns
Patients with incomplete palliation 6/48 (12.5%) 5/32 (15.6%) 1/16 (6.25%) ns
Patients with overt heart failure 6/48 (12.5%) 4/32 (12.5%) 2/16 (12.5%) ns
NYHA functional class 1.5 ± 0.7 1.5 ± 0.8 1.6 ± 0.7 ns
Systolic blood pressure (mmHg) 121.4 ± 14.5 123.2 ± 14.9 117.8 ± 13.4 ns
Diastolic blood pressure (mmHg) 66.0 ± 9.9 66.2 ± 10.7 65.6 ± 8.1 ns
Transcutaneous oxygen saturation at rest (%) 91.7 ± 5.3 91.3 ± 5.9 92.3 ± 4.1 ns
Ejection fraction of SV (%) 54.9 ± 6.6 55.3 ± 5.9 54.3 ± 8.1 ns
Enddiastolic volume of SV (ml) 145.6 ± 58.3 133.1 ± 54.7 170.7 ± 58.8 ns
Endsystolic volume of SV (ml) 67.3 ± 31.0 60.9 ± 26.7 80.1 ± 35.7 ns




































UVH, univentricular heart; NYHA, New York Heart Association; LV, left ventricle; RV, right ventricle; SV, systemic ventricle; VTI, velocity time integral; eGFR,
estimated glomerular filtration rate; ns, not significant.
Mean ± standard deviation or median (interquartile interval) are used.
� LV compared to RV subgroup.
https://doi.org/10.1371/journal.pone.0223606.t001
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PCR with exon spanning primers for Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH)
was performed. The concentration of isolated total RNA was measured using NanoDrop ND-
2000 spectrophotometer (Thermo Fisher Scientific, Massachusetts, United States). RNA purity
was estimated by examining the OD 260/280 and the OD 260/230 ratios. The qualities of total
RNA were assessed using the Agilent Bioanalyser 2100 Eukaryote Total RNA Nano Series II
(Agilent Technologies, California, United States).
Analysis of miRNAs by microarray
MiRNA abundance analysis was performed on the isolated miRNA fraction in 48 patients
with UVH and 32 age- and gender-matched healthy controls using SurePrint™8X60K Human
v21 miRNA microarrays (Agilent Technologies) according to the manufacturer’s instructions.
In total, an input amount of 100 ng of isolated RNA including miRNAs was labeled and subse-
quently hybridized to the miRNA microarray chip [25]. Subsequently, data were imported
into R statistical environment software v.2.14.2 for analysis. Microarray data are available at
the Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/) under the accession number
GSE 136547.
Analysis of miRNAs by RT-qPCR
Real-time quantitative PCR (RT-qPCR) validation analysis was performed using the StepOne-
Plus™ Real-Time PCR System (Applied Biosystems, Foster City, CA, United States) and the
miScript PCR System (Qiagen) according to the manufacturer’s instructions. For miRNA
abundance level detection, 250 ng of the total RNA were converted into complementary DNA
(cDNA). The resulting cDNA was then diluted to have 0.5 ng/μL input material for miRNA
detection. All RT-qPCR experiments were carried out using the Liquid Handling Robot QIA-
gility™ (Qiagen) before performing RT-qPCR. All primer assays used in the current study were
provided by Qiagen. Moreover, miRNA reverse transcription control (miRTC) (Qiagen) was
performed to assess the performance of the reverse transcription reaction. The melting curve
analysis was used to control the specificity of RT-qPCR products. Specificity of amplicons was
further confirmed by agarose gel electrophoresis.
Data analysis
Clinical data of the patients were collected from medical records. Echocardiography was per-
formed using a Vivid™ E9 Ultrasound System (GE Healthcare, Horten, Norway). The echocar-
diographic loops and Doppler images were stored digitally and analysed on an Echopac server
(Echopac Version 6, GE Healthcare) as has been described previously [24]. Echocardiographic
data sets were assessed by investigators blinded to the laboratory results. Investigators of
miRNA signatures were blinded to the clinical, echocardiographic and laboratory data of the
patients.
Statistical analysis
Raw data generated by Agilent Feature Extraction image analysis software was quantile nor-
malized and the differentially abundant miRNAs in patients versus age- and gender- matched
healthy control samples were determined using the R statistical environment v.2.14.2 software.
A significance level of miRNAs was analyzed by applying an unpaired two-tailed t test, cor-
rected p-value (<0.05, Benjamini-Hochberg False Discovery Rate (FDR) multiple testing cor-
rection method), 1.5-fold change cut-off, and area under the receiver operating characteristic
curve (AUC) values for each miRNA were computed. For RT-qPCR, the DataAssist™ Software
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v3.0 (Applied Biosystems) was used to calculate the fold-changes in miRNA expression by the
equation 2−ΔCt with RNU6B serving as an endogenous control [26].
Clinical data were analysed using standard statistical software (SPSS version 19; SPSS Inc.,
Chicago, Illinois). Continuous variables are expressed as mean ± standard deviation or median
(interquartile interval) as appropriate. Differences between unpaired groups were analysed
using a Mann-Whitney-U test for continuous variables and a chi-square test (or Fisher exact
test, if numbers were small) for nominal variables. Correlations were evaluated using Spear-
man’s regression coefficient. For further analysis, biomarker levels were log10 transformed due
to the skewed distribution of the data. Receiver-operating characteristic (ROC) curve analysis
was used for the prediction of overt heart failure and all-cause mortality. Logistic regression
analysis was used and implemented into ROC curve analysis in order to evaluate the AUC of
combined biomarker models and to assess their potential additive value. Comparison of AUCs
was performed using the DeLong method [27]. Multivariate analysis was performed using Cox
regression analysis in a stepwise forward manner to identify independent predictors of overt
heart failure and all-cause mortality. Variables entered into the multivariate model were those
that gave statistically significant results in the univariate analysis. A two-tailed p-value <0.05
was considered statistically significant.
Results and discussion
Results
Identification of abundant miRNAs. To identify miRNAs that were differentially abun-
dant in the blood of patients with UVH and healthy controls, we analyzed abundance level of
2549 human mature miRNAs of miRBase v21. Following background correction and quantile
normalization, abundance levels of circulating miRNAs were screened and an unpaired t-test
was performed to identify those miRNAs that showed significantly abundant levels in patients
with UVH compared to healthy controls. Finally, using Benjamini-Hochberg FDR <0.05 and
1.5 fold change cut-off, 20 down-regulated and 30 up-regulated miRNAs were found in our
cohort of patients (S1 Table). Correlation analyses of these abundantly expressed miRNAs to
clinical measures of heart failure such as NYHA class, a higher NYHA class� III and the
occurrence of overt heart failure were performed identifying miR-125a-5p and miR-150-5p to
be the most significant miRNAs. Thus, these two miRNAs were further validated by RT-qPCR
indicating significantly lower expression levels in UVH patients compared to healthy controls
(Fig 1).
Correlation of miRNAs with clinical data. During follow-up, overt heart failure requir-
ing intensified medical therapy or rehospitalization occurred in 6/48 (12.5%) patients. In these
patients, normalized expression levels of miR-150-5p were significantly lower than in patients
without occurrence of overt heart failure (p<0.001) thus indicating significant downregulation
of miR-150-5p prior to acute decompensation (Fig 2). Moreover, 6/48 (12.5%) patients died of
whom 2 patients due to sudden cardiac death, 3 patients due to progressive heart failure and 1
patient due to septicemia.
Relations of miR-125a-5p and miR-150-5p validated by RT-qPCR to clinical, echocardio-
graphic and laboratory parameters are given in Table 2.
Prediction of overt heart failure. ROC curve analysis was used to identify predictors of
overt heart failure in all patients. The most significant predictors were NT-proBNP levels,
miR-150-5p, a higher NYHA class� III and high sensitive troponin T levels, respectively.
Multivariate analysis identified a higher NYHA class� III (p = 0.005) and miR-150-5p
(p = 0.006) as independent predictors of overt heart failure (Table 3).
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The use of a combined model consisting of NT-proBNP and miR-150-5p demonstrated an
increase of the AUC to 0.980 (p = 0.116) indicating a potential additive value of miR-150-5p
for the prediction of overt heart failure (Fig 3).
Prediction of all-cause mortality. According to ROC curve analysis, the most significant
predictors of all-cause mortality were NT-proBNP levels, high sensitive troponin T levels, a
higher NYHA class� III and miR-150-5p, respectively. In the multivariate analysis, NYHA
class� III (p<0.001) was found to be the most significant independent predictor of all-cause
mortality (Table 3). Moreover, AUC only increased slightly to 0.956 using a combined model
of NT-proBNP and miR-150-5p (p = 0.675), thus indicating no additive value of miR-150-5p
in predicting all-cause mortality (Fig 4).
Fig 1. Boxplots displaying normalized expression levels of miR-125a-5p and miR-150-5p in patients with UVH (n = 48) compared to healthy
controls (n = 32). UVH, univentricular heart.
https://doi.org/10.1371/journal.pone.0223606.g001
Fig 2. Boxplots illustrating normalized expression levels of miR-125a-5p and miR-150-5p in UVH patients with (n = 6) and without (n = 42)
occurrence of overt heart failure. UVH, univentricular heart; HF, heart failure.
https://doi.org/10.1371/journal.pone.0223606.g002
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Discussion
In patients with left heart failure, miRNAs have been shown to be of diagnostic and prognostic
value [16, 18]. Moreover, in patients with tetralogy of Fallot, expression levels of specific miR-
NAs may indicate the presence of symptomatic heart failure [22]. Thus, the aim of our study
was to identify these miRNAs in UVH patients that are significantly associated with clinical
measures of heart failure and to assess their predictive value in this cohort of patients.
Table 2. Correlation of miRNAs validated by RT-qPCR with clinical, echocardiographic and laboratory parame-
ters (n = 48).
miR-125a-5p miR-150-5p
r p-value r p-value
NYHA functional class -0.307 0.034 -0.379 0.008
Higher NYHA class� III - ns -0.394 0.006
Occurrence of overt heart failure - ns -0.459 0.001
Death from any cause -0.298 0.040 -0.382 0.007
Ejection fraction of SV - ns - ns
VTI above aortic valve - ns - ns
Albumin - ns - ns
γGT - ns - ns
eGFR - ns - ns
NT-proBNP - ns - ns
High sensitive troponin T - ns -0.383 0.007
NYHA, New York Heart Association; SV, systemic ventricle; VTI, velocity time integral; eGFR, estimated glomerular
filtration rate; ns, not significant.
https://doi.org/10.1371/journal.pone.0223606.t002
Table 3. Results of ROC curve and multivariate analysis for the prediction of overt heart failure and all-cause mortality.
Prediction of overt heart failure
Variables AUC 95% CI p-value Multivariate analysis (p-value)
NT-proBNP log10 0.940 0.873–1.000 0.001 0.322
miR-150-5p 0.905 0.779–1.000 0.001 0.006; HR 19.333
(95% CI 1.553–240.706)
NYHA class� III 0.893 0.713–1.000 0.002 0.005; HR 15.656
(95% CI 1.675–146.369)
High sensitive troponin T log10 0.861 0.733–0.990 0.005 0.639
Albumin 0.732 0.435–1.000 0.068 Not included
miR-125a-5p 0.724 0.563–0.886 0.078 Not included
Prediction of all-cause mortality
Variables AUC 95% CI p-value Multivariate analysis (p-value)
NT-proBNP log10 0.948 0.887–1.000 <0.001 0.695
High sensitive troponin T log10 0.897 0.779–1.000 0.002 0.364
NYHA class� III 0.893 0.713–1.000 0.002 <0.001; HR 36.569
(95% CI 4.255–314.317)
miR-150-5p 0.837 0.693–0.982 0.008 0.084
Albumin 0.778 0.498–1.000 0.029 Not included
miR-125a-5p 0.760 0.590–0.930 0.041 Not included
AUC, area under the curve; CI, confidence interval; HR, hazard ratio; NYHA, New York Heart Association.
https://doi.org/10.1371/journal.pone.0223606.t003
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Association of miRNAs with clinical status. In our study, miR-125a-5p and miR-150-5p
have been found to be best associated with clinical measures of heart failure in UVH patients
using microarray analysis. However, after validation by RT-qPCR, miR-150-5p only turned
out to be significantly related to a higher NYHA class or the occurrence of overt heart failure
(Table 2). Moreover, miR-150-5p was significantly down-regulated in UVH patients prior to
the occurrence of overt heart failure (Fig 2) indicating its pathophysiological relevance of
downregulation for heart failure progression or even acute worsening of heart failure. Our
results are in line with those found in patients with left heart failure in whom miR-150-5p
turned out to be significantly downregulated in those patients with advanced left heart failure
or in patients with chronic systolic left heart failure and atrial fibrillation reflecting disease pro-
gression and a poor outcome in those patients [28, 29]. Moreover, initial studies have demon-
strated that low levels of miR-150-5p predict adverse left ventricular remodeling in patients
after acute myocardial infarction [30, 31].
It is of note that miR-150-5p levels were inversely related to measures of heart failure and
outcome in our study. Although most of published studies report on positive associations
between different circulating miRNAs and outcome, our results are in agreement with previ-
ous studies showing a negative association of circulating miR-150-5p with disease severity and
outcome in patients with left heart failure [28]. This finding may be due to the fact that miR-
150-5p exerts anti-apoptotic functions by directly suppressing distinct pro-apoptotic genes
[32] or by inhibiting p53 activity which is a major inducer of apoptosis [33]. As a result, defi-
ciency of miR-150-5p activates apoptosis signaling in cardiomyocytes which is crucial for the
progression of heart failure.
In contrast, our results are not in agreement with a study conducted in children with UVH
disease in whom miR-129-5p was found to be a sensitive and specific biomarker for heart fail-
ure irrespective of ventricular morphology and stage of palliation [23]. However, in that study,
a panel of only 5 miRNAs was evaluated not including miR-125a-5p or miR-150-5p. More-
over, the conceptualization of that study did not include a control group and thus was
completely different to our study design, which comprised a large panel of miRNAs as well as
age- and gender-matched controls in order to select the most differentially expressed miRNAs.
Prediction of overt heart failure. The most significant predictors of overt heart failure in
our cohort of patients were NT-proBNP levels, miR-150-5p, a higher NYHA class� III and
high sensitive troponin T levels with an AUC of 0.940, 0.905, 0.893 and 0.861, respectively. A
higher NYHA class� III as well as miR-150-5p turned out to be the strongest independent
predictors in the multivariate analysis (p = 0.005 and p = 0.006, respectively). In contrast, echo-
cardiographic measures of heart failure such as ejection fraction of the systemic ventricle or
velocity time integral were not predictive of overt heart failure what is not surprising because
measurement of these variables is sophisticated due to the heterogeneity of the underlying car-
diac malformations and different loading conditions [34]. Moreover, using a combined model
of NT-proBNP and miR-150-5p, AUC increased to 0.980 with an AUC difference of NT-
proBNP and the combined model of 0.04 (p = 0.116) indicating that miR-150-5p may have
potential additive value to NT-proBNP for the prediction of overt heart failure (Fig 3). Overall,
our results are in agreement with previous studies demonstrating that downregulation of miR-
150-5p seems to play an important role in the progression and deterioration of left heart failure
and thus might also yield prognostic impact [28–31].
Prediction of all-cause mortality. In our study population, all-cause mortality was best
predicted by NT-proBNP levels, high sensitive troponin T levels, a higher NYHA class� III
and miR-150-5p with an AUC of 0.948, 0.897, 0.893 and 0.837, respectively. In the multivariate
analysis, however, a higher NYHA class� III was the only independent predictor of all-
cause mortality (p<0.001). Furthermore, only a slight increase of AUC was seen with the
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combination of NT-proBNP and miR-150-5p in the ROC curve analysis (Fig 4). Obviously,
miR-150-5p seems to be specific for the prediction of overt heart failure but doesn’t add for
the prediction of death from any cause. The lack of an additive value for the prediction of all-
cause mortality may be due to the fact that mortality was not heart-failure related in 50% of the
deceased patients in our study cohort. Nevertheless, natriuretic peptides, troponin T as well as
NYHA class are known to be strong predictors of all-cause mortality in patients with congeni-
tal heart disease in general but also high-risk subgroups [35, 36].
Study limitations. This is the first study that aims to characterize signatures of miRNAs
in adolescent and adult patients with UVH using a large panel of more than 2000 miRNAs for
initial screening in order to identify those that are involved in the progression of heart failure
and might have predictive value in this cohort of patients. Since UVH disease is a rare congeni-
tal cardiac disorder, sample size of our patient cohort is rather small and event rate rather low.
Especially the number of patients with heart-failure related death is too small to assess the
prognostic value of miR-150-5p what would have been most interesting and probably under-
lined its heart-failure specific profile. Hence, a larger cohort of UVH patients and also a larger
control group should be evaluated to provide further insights into the role of miRNAs in these
patients.
Fig 3. Receiver-operating characteristic (ROC) curves comparing sensitivity and specificity of NT-proBNP and
miR-150-5p in predicting overt heart failure. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0223606.g003
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Another important aspect is the cellular and extracellular origin of miRNAs in our study.
Although the ratio of cellular and extracellular miRNA might be different using PAX gene
tubes instead of serum or plasma samples, previous studies have shown that disease-associated
miRNA signatures originate from the tissues affected by the disease and that extracellular
miRNA profiles accurately reflect those signatures found in tissue samples [17, 37, 38]. On the
other hand, it is known that expression profiles of extracellular miRNAs may also vary accord-
ing to the methodology of sample preparation [39] and that normalization methods of extra-
cellular miRNAs have not yet been standardized [38, 40] resulting in inconsistent findings
across studies.
Conclusions
In patients with UVH, miR-150-5p represents an independent predictor of overt heart failure
and is significantly down-regulated in patients prior to the occurrence of overt heart failure.
Moreover, it seems to have potential additive value to natriuretic peptides for the prediction of
overt heart failure and thus may be used as additional biomarker in the risk assessment of
these patients.
Fig 4. Receiver-operating characteristic (ROC) curves comparing sensitivity and specificity of NT-proBNP and
miR-150-5p in predicting all-cause mortality. AUC, area under the curve.
https://doi.org/10.1371/journal.pone.0223606.g004
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